Radiation Therapy in Prostate Cancer

Radiation therapy is one of the main local treatment options in prostate cancer. It may be used with curative intent as an alternative to surgery, after surgery in selected settings, together with hormone therapy in higher-risk disease, or for symptom control in metastatic situations. Which role it plays depends on tumour stage, grade, PSA, imaging findings, age, baseline function, and patient preference. ^[1][2][3]

What is the role of radiation therapy in prostate cancer?

For many men with localised prostate cancer, radiotherapy can offer cancer control outcomes comparable to surgery when appropriately selected and delivered. That does not mean the two paths are identical. They differ in logistics, side-effect patterns, how PSA behaves afterward, and how urinary or sexual function may change over time. In some patients, radiotherapy is chosen because surgery is less desirable; in others, it is selected because it fits the tumour and the patient’s priorities well. ^[1][2][4]

Radiation may also be used after prostatectomy in selected cases—for example when pathology suggests higher recurrence risk or when PSA rises again. In more advanced disease, it may be combined with androgen-deprivation therapy to improve control. Therefore, “radiotherapy for prostate cancer” is not a single scenario. It spans curative, adjuvant, salvage, and palliative uses. ^[1][2][5]

Which types of radiation can be used?

Common techniques include external beam radiotherapy such as IMRT/IGRT and, in selected patients, brachytherapy. Some treatment plans use brachytherapy as a boost combined with external beam therapy. The choice depends on prostate size, urinary symptoms, anatomy, risk category, and centre expertise. Hypofractionated schedules have also become increasingly important, allowing treatment in fewer sessions for appropriate patients. ^[1][2][6]

How are preparation and planning performed before treatment?

Before treatment begins, imaging, contouring, and precise planning are required to deliver dose to the prostate while protecting surrounding tissues such as the rectum and bladder as much as possible. Some centres use fiducial markers, rectal spacers, or image guidance to improve targeting. The quality of planning matters because good radiotherapy is not just about the machine—it is about accurate volume definition, reproducibility, and safe dose distribution. ^[1][2][6]

How does the treatment process affect the patient?

External beam radiotherapy is usually delivered over multiple outpatient sessions. The treatment itself is not felt in the moment the way pain is felt, but cumulative side effects can emerge during the course. Common effects include urinary frequency, urgency, burning, bowel irritation, fatigue, and sometimes gradual changes in sexual function. Their severity varies with baseline function, total dose, field design, and whether hormone therapy is also used. ^[1][2][3]

What are the side effects and long-term risks?

Side effects can be short-term or delayed. Early urinary and bowel symptoms are relatively common, while late effects may include persistent urinary irritation, rectal bleeding, erectile dysfunction, or urethral complications in selected cases. Patients should be counselled that “less invasive than surgery” does not mean “free of long-term effects.” The side-effect profile is different, not absent. ^[1][2][5]

Shorter schedules and recent developments

Hypofractionated and in some settings ultrahypofractionated schedules have changed the treatment experience for many patients by shortening the number of visits. These regimens require careful patient selection and high-quality image guidance, but they demonstrate how prostate radiotherapy continues to evolve. ^[1][2][6]

Follow-up after treatment and when to contact a doctor

PSA usually declines over time after radiotherapy rather than becoming immediately undetectable as it often does after prostatectomy. That pattern can be confusing for patients. Follow-up therefore focuses on PSA trend, symptoms, imaging where needed, and the management of urinary, bowel, and sexual function. Urgent review is needed for inability to pass urine, heavy rectal bleeding, severe pain, or major deterioration in general condition. ^[1][2][5]

Why may it be planned together with hormone therapy?

In intermediate- and high-risk disease, combining radiotherapy with androgen-deprivation therapy may improve cancer control. The duration and intensity of hormone treatment depend on risk category and treatment intent. ^[1][2][4]

How can daily life, work, and sexual health be affected?

Many patients can continue some daily activities during treatment, but fatigue and session schedules can make work more difficult. Sexual function may change gradually rather than immediately, and bowel or urinary effects can influence quality of life. Honest pre-treatment counselling helps patients compare this pathway fairly against surgery or surveillance. ^[1][2][3]